Table 2.
Summary of Effects of Denosumab on Bone Turnover and Bone Mineral Density in Patients Receiving Glucocorticoids.
| Reference | No. of patients | Serum levels of biomarkers | Bone mineral density | Others | ||||
|---|---|---|---|---|---|---|---|---|
| CTX or NTX | P1NP | LS | TH | FN | ||||
| 7 | 28* | approx. - 61% | approx. - 47% | approx. 3.0% | approx.1.3% | ND | ||
| 8 | 30* | ND | ND | 5.8% | 2.3% | ND | ||
| 9 | 14 | ND | ND | ND | ND | ND | BMSi: 15%** | |
| 10 | 21* | - 30% | -15% | 3.4% | 1.4% | - 0.1% | ||
| Present study | 29* | - 28% | ND | 3.5% | ND | 3.0% | BAP: - 23% | |
Values of biomarkers and bone mineral density are percentages vs. baseline.
*Treated with denosumab 60 mg once every 6 months for 2 doses
**At 20 weeks
BAP: bone type-specific alkaline phosphatase, BMSi: Bone material strength index, CTX: C-terminal cross-linked telopeptide of type 1 collagen, FN: femoral neck, LS: lumbar spine, ND: not determined, NTX: N-terminal cross-linked telopeptide of type 1 collagen, P1NP: procollagen type 1 N-terminal propeptide, TH: total hip.